
|Videos|October 24, 2022
Dr. Rana McKay on practice-changing trials in advanced renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Rana McKay, MD, describes the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials, which she says, “have largely changed the way we treat kidney cancer in the modern era for patients with advanced/metastatic disease.” McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












